Sol Gel Technologies Ltd
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.35
- Today's High:
- $2.605
- Open Price:
- $2.51
- 52W Low:
- $2.35
- 52W High:
- $6
- Prev. Close:
- $2.51
- Volume:
- 6648
Company Statistics
- Market Cap.:
- $77.86 million
- Book Value:
- 1.737
- Revenue TTM:
- $1.26 million
- Operating Margin TTM:
- -2183.2%
- Gross Profit TTM:
- $-8799000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -31.14%
- Return on Equity TTM:
- -52.48%
Company Profile
Sol Gel Technologies Ltd had its IPO on 2018-01-23 under the ticker symbol SLGL.
The company operates in the Healthcare sector and Biotechnology industry. Sol Gel Technologies Ltd has a staff strength of 55 employees.
Stock update
Shares of Sol Gel Technologies Ltd opened at $2.51 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.35 - $2.61, and closed at $2.51.
This is a +0.03% increase from the previous day's closing price.
A total volume of 6,648 shares were traded at the close of the day’s session.
In the last one week, shares of Sol Gel Technologies Ltd have slipped by -8.7%.
Sol Gel Technologies Ltd's Key Ratios
Sol Gel Technologies Ltd has a market cap of $77.86 million, indicating a price to book ratio of 2.2557 and a price to sales ratio of 4.2798.
In the last 12-months Sol Gel Technologies Ltd’s revenue was $1.26 million with a gross profit of $-8799000 and an EBITDA of $-27001000. The EBITDA ratio measures Sol Gel Technologies Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Sol Gel Technologies Ltd’s operating margin was -2183.2% while its return on assets stood at -31.14% with a return of equity of -52.48%.
In Q2, Sol Gel Technologies Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a negative 83.1%.
Sol Gel Technologies Ltd’s PE and PEG Ratio
- Forward PE
- 9.3371
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.05 per share while it has a forward price to earnings multiple of 9.3371 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Sol Gel Technologies Ltd’s profitability.
Sol Gel Technologies Ltd stock is trading at a EV to sales ratio of 2.9553 and a EV to EBITDA ratio of 18.5434. Its price to sales ratio in the trailing 12-months stood at 4.2798.
Sol Gel Technologies Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $55.10 million
- Total Liabilities
- $5.67 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Sol Gel Technologies Ltd ended 2024 with $55.10 million in total assets and $0 in total liabilities. Its intangible assets were valued at $55.10 million while shareholder equity stood at $48.30 million.
Sol Gel Technologies Ltd ended 2024 with $0 in deferred long-term liabilities, $5.67 million in other current liabilities, 771000.00 in common stock, $-209756000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $15.62 million and cash and short-term investments were $46.98 million. The company’s total short-term debt was $433,000 while long-term debt stood at $0.
Sol Gel Technologies Ltd’s total current assets stands at $51.59 million while long-term investments were $0 and short-term investments were $31.36 million. Its net receivables were $2.21 million compared to accounts payable of $461000.00 and inventory worth $0.
In 2024, Sol Gel Technologies Ltd's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Sol Gel Technologies Ltd paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.51
- 52-Week High
- $6
- 52-Week Low
- $2.35
- Analyst Target Price
- $11.17
Sol Gel Technologies Ltd stock is currently trading at $2.51 per share. It touched a 52-week high of $6 and a 52-week low of $6. Analysts tracking the stock have a 12-month average target price of $11.17.
Its 50-day moving average was $3.09 and 200-day moving average was $3.82 The short ratio stood at 2.08 indicating a short percent outstanding of 0%.
Around 5094.3% of the company’s stock are held by insiders while 2900.4% are held by institutions.
Frequently Asked Questions About Sol Gel Technologies Ltd
Similar Industry Stocks (Biotechnology)
-1.7%
Most Active
Top Gainers
Top Losers
About
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company’s lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; SGT-610, a rare disease for the treatment of Gorlin Syndrome which has completed Phase II clinical trials; and Erlotinib and Tapinarof to treat other rare skin indications. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.